Beyond hyperglycemia: glycaemic variability as a prognostic factor after acute ischemic stroke.

Abstract

Glycaemic variability (GV) refers to variations in blood glucose levels, and may affect stroke outcomes. This study aims to assess the effect of GV on acute ischaemic stroke progression. We performed an exploratory analysis of the multicentre, prospective, observational GLIAS-II study. Capillary glucose levels were measured every 4hours during the first 48hours after stroke, and GV was defined as the standard deviation of the mean glucose values. The primary outcomes were mortality and death or dependency at 3 months. Secondary outcomes were in-hospital complications, stroke recurrence, and the impact of the route of insulin administration on GV. A total of 213 patients were included. Higher GV values were observed in patients who died (n=16; 7.8%; 30.9mg/dL vs 23.3mg/dL; p=0.05). In a logistic regression analysis adjusted for age and comorbidity, both GV (OR=1.03; 95% CI, 1.003-1.06; p=0.03) and stroke severity (OR=1.12; 95% CI, 1.04-1.2; p=0.004) were independently associated with mortality at 3 months. No association was found between GV and the other outcomes. Patients receiving subcutaneous insulin showed higher GV than those treated with intravenous insulin (38.95mg/dL vs 21.34mg/dL; p<0.001). High GV values during the first 48hours after ischaemic stroke were independently associated with mortality. Subcutaneous insulin may be associated with higher VG levels than intravenous administration.